Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle

Barbara M Parker; Sara L Rogers; Anastasios Lymperopoulos

doi:10.2217/pgs-2018-0115

Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle

Pharmacogenomics. 2018 Sep 1;19(14):1089-1093. doi: 10.2217/pgs-2018-0115. Epub 2018 Aug 8.

Authors

Barbara M Parker¹, Sara L Rogers², Anastasios Lymperopoulos¹

Affiliations

¹ Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University College of Pharmacy, Ft. Lauderdale, FL 33328, USA.
² American Society of Pharmacovigilance, Houston, TX 77225, USA.

PMID: 30086658
DOI: 10.2217/pgs-2018-0115

No abstract available

Keywords: CYP2D6; P-glycoprotein; carvedilol; drug interactions; enantiomer; heart failure; pharmacokinetics; polymorphism; stereo-selective metabolism; β-blocker.

Publication types

Editorial

MeSH terms

Adrenergic beta-Antagonists / pharmacokinetics
Carvedilol / pharmacokinetics*
Female
Heart Failure / genetics
Heart Failure / metabolism
Humans
Male
Myocardium / metabolism
Pharmacogenetics / methods
Polymorphism, Genetic / genetics
Receptors, Adrenergic / genetics

Substances

Adrenergic beta-Antagonists
Receptors, Adrenergic
Carvedilol